The epidemiology study in multiple sclerosis - Relevance to natural history

McGill Journal of Medicine

Volumn 7, Issue 1, 2002, Pages 41-50

  Scott Sloka, J ^a,b  

^a Memorial University of Newfoundland ^*  (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMNESIS; CLUSTER ANALYSIS; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; PREVALENCE; PUBLICATION; RELAPSE; REMISSION; REVIEW;

EID: 34748814285     PISSN: 1201026X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Paty DW, Ebers GC. Multiple Sclerosis. Contemporary Neurology Series 1998; 50:Chapter 4 - Diagnosis.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343(13):938-952.
3. Wolfson MC. Health-adjusted life expectancy. Health Rep 1996; 8(1):41-46.
4. Lauer K. Ecologic studies of multiple sclerosis. Neurology 1997; 49(2 Suppl 2):S18-S26.
5. Hodge MJ, Wolfson C. Canine distemper virus and multiple sclerosis. Neurology 1997; 49(2 Suppl 2):S62-S69.
6. Hernan MA, Zhang SM, Lipworth L, Olek MJ, Ascherio A. Multiple sclerosis and age at infection with common viruses. Epidemiology 2001; 12(3):301-306.
7. Landtblom AM. Exposure to organic solvents and multiple sclerosis. Neurology 1997; 49(2 Suppl 2):S70-S74.
8. Lauer K. Diet and multiple sclerosis. Neurology 1997; 49(2 Suppl 2):S55-S61.
9. Irvine DG, Schiefer HB, Hader WJ. Geotoxicology of multiple sclerosis: the Henribourg, Saskatchewan, cluster focus. II. The soil. Sci Total Environ 1988; 77(2-3):175-188.
10. Fukazawa T, Yamasaki K, Ito H, Kikuchi S, Minohara M, Horiuchi I et al. Both the HLA-CPB1 and -DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. Tissue Antigens 2000; 55(3):199-205.
11. Marrosu MG, Murru MR, Costa G, Murru R, Muntoni F, Cucca F. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet 1998; 7(8):1235-1237.
12. Lucchinetti C, Bruck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001; 14(3):259-269.
13. Lucchinetti CF, Rodriguez M. The controversy surrounding the pathogenesis of the multiple sclerosis lesion. Mayo Clin Proc 1997; 72(7):665-678.
14. McCall MG, Brercton TL, Dawson A, Millingen K, Sutherland JM, Acheson ED. Frequency of multiple sclerosis in three Australian cities - Perth, Newcastle, and Hobart. J Neurol Neurosurg Psychiatry 1968; 31(1):1-9.
15. Hammond SR, McLeod JG, Millingen KS, Stewart-Wynne EG, English D, Holland JT et al. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988; 111 (Pt 1):1-25.
16. Compston A. The epidemiology of multiple sclerosis: principles, achievements, and recommendations. Ann Neurol 1994; 36 Suppl 2:S211-S217.
17. Hibberd PL. Use and misuse of statistics for epidemiological studies of multiple sclerosis. Ann Neurol 1994; 36 Suppl 2:S218-S230.
18. Lauer K. Ecologic studies of multiple sclerosis. Neurology 1997; 49(2 Suppl 2):S18-S26.
19. Poser CM, Benedikz J, Hibberd PL. The epidemiology of multiple sclerosis: the Iceland model. Onset- adjusted prevalence rate and other methodological considerations. J Neurol Sci 1992; 111(2):143-152.
20. Compston A. The epidemiology of multiple sclerosis: principles, achievements, and recommendations. Ann Neurol 1994; 36 Suppl 2:S211-S217.
21. Boiko A. Data collection guidelines for questionnaires to be used in case- control studies of multiple sclerosis. Neurology 1997; 49(2 Suppl 2):S75-S80.
22. Kurtzke JF. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. Neurol Sci 2000; 21(6):383-403.
23. Compston A. Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 62(6):553-561.
24. Cowan LD, Leviton A, Dammann O. New research directions in neuroepidemiology. Epidemiol Rev 2000; 22(1):18-23.
25. Granieri E, Casetta I, Tola MR. A multicenter study methodologic experience from a multicenter case- control study in Italy. The Italian Multiple Sclerosis Study Group. Neurology 1997; 49(2 Suppl 2):S33-S41.
26. Lauer K. Environmental associations with the risk of multiple sclerosis: the contribution of ecological studies. Acta Neurol Scand Suppl 1995; 161:77-88.
27. Weinshenker BG. Epidemiologic strategies to detect an exogenous cause of MS. Acta Neurol Scand Suppl 1995; 161:93-99.
28. Pryse-Phillips WE. The incidence and prevalence of multiple sclerosis in Newfoundland and Labrador, 1960-1984. Ann Neurol 1986; 20(3):323-328.
29. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000; 123 (Pt 6):1102-1111.
30. Hader WJ, Elliot M, Ebers GC. Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada. Neurology 1988; 38(4):617-621.
31. Warren S, Warren KG. Prevalence, incidence, and characteristics of multiple sclerosis in Westlock County, Alberta, Canada. Neurology 1993; 43(9):1760-1763.
32. Warren S, Warren KG. Prevalence of multiple sclerosis in Barrhead County, Alberta, Canada. Can J Neurol Sci 1992; 19(1):72-75.
33. Klein GM, Rose MS, Seland TP. A prevalence study of multiple sclerosis in the Crowsnest Pass region of southern Alberta. Can J Neurol Sci 1994; 21(3):262-265.
34. Sweeney VP, Sadovnick AD, Brandejs V. Prevalence of multiple sclerosis in British Columbia. Can J Neurol Sci 1986; 13(1):47-51.
35. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 1998; 27(5):845-852.
36. Granieri E, Casetta I, Tola MR. A multicenter study methodologic experience from a multicenter case- control study in Italy. The Italian Multiple Sclerosis Study Group. Neurology 1997; 49(2 Suppl 2):S33-S41.
37. Esbjerg S, Keiding N, Koch-Henriksen N. Reporting delay and corrected incidence of multiple sclerosis. Stat Med 1999; 18(13):1691-1706.
38. Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 1999; 107 Suppl 5:693-700.
39. Weinshenker BG. Epidemiologic strategies to detect an exogenous cause of MS. Acta Neurol Scand Suppl 1995; 161:93-99.
40. Rothman KJ. Induction and latent periods. Am J Epidemiol 1981; 114(2):253-259.
41. Fischman HR. Multiple sclerosis: a two-stage process? Am J Epidemiol 1981; 114(2):244-252.
42. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995; 377(6545):150-151.
43. Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33(3):281-285.
44. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A, Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2(7840):1221-1225.
45. Schrijver HM, Crusius JB, Uitdehaag BM, Garcia Gonzalez MA, Kostense PJ, Polman CH et al. Association of interleukin-1lbeta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 1999; 52(3):595-599.
46. Myhr KM, Raknes G, Nyland H, Vedeler C. Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS. Neurology 1999; 52(9):1771-1776.
47. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67(2):203-205.
48. Acheson ED. Epidemiology of multiple sclerosis. Br Med Bull 1977; 33(1):9-14.
49. Vassallo L, Elian M, Dean G. Multiple sclerosis in southern Europe. II: Prevalence in Malta in 1978. J Epidemiol Community Health 1979; 33(2):111-113.
50. Dean G, Grimaldi G, Kelly R, Karhausen L. Multiple sclerosis in southern Europe. I: Prevalence in Sicily in 1975. J Epidemiol Community Health 1979; 33(2):107-110.
51. Leibowitz U, Kahana E, Alter M. The changing frequency of multiple sclerosis in Israel. Arch Neurol 1973; 29(2):107-110.
52. Alter M, Kahana E, Loewenson R. Migration and risk of multiple sclerosis. Neurology 1978; 28(11):1089-1093.
53. Alter M, Okihiro M, Rowley W, Morris T. Multiple sclerosis among Caucasians and Orientals in Hawaii. Neurology 1970; 20(4):399.
54. Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age at immigration to Israel. Arch Neurol 1966; 15(3):234-237.
55. Dean G, Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63(5):565-568.
56. Detels R, Visscher BR, Haile RW, Malmgren RM, Dudley JP, Coulson AH. Multiple sclerosis and age at migration. Am J Epidemiol 1978; 108(5):386-393.
57. Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000; 123 (Pt 5):968-974.
58. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995; 47(4-5):425-448.
59. Hammond SR, English D, de Wytt C, Maxwell IC, Millingen KS, Stewart-Wynne EG et al. The clinical profile of MS in Australia: a comparison between medium- and high-frequency prevalence zones. Neurology 1988; 38(6):980-986.
60. Alter M, Halpern L, Bornstein B. Multiple Sclerosis in Israel. Arch Neurol 1962; 7:253-263.
61. Kurland L, Reed D. Geographic and climatic aspects of multiple sclerosis: a review of current hypotheses. Am J Public Health 1964; 54:588-597.
62. Larsen JP, Kvaale G, Riise T, Nyland H, Aarli JA. Multiple sclerosis-more than one disease? Acta Neurol Scand 1985; 72(2):145-150.
63. Weinshenker BG. Progressive forms of MS: classification streamlined or consensus overturned? Lancet 2000; 355(9199):162-163.
64. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4):907-911.
65. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 122 (Pt 10):1941-1950.
66. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103(2):281-300.
67. Bashir K, Whitaker JN. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 1999; 53(4):765-771.
68. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis: a distinct syndrome? Mult Scler 1996; 2(3):137-141.
69. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112 (Pt 1):133-146.
70. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi MM, X et al. Primary progressive multiple sclerosis. Brain 1997; 120 (Pt 6):1085-1096.
71. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, Lapierre Y et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43(5):910-918.
72. Goodkin DE, Rudick RA, VanderBrug MS, Daughtry MM, Schwetz KM, Fischer J et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37(1):30-40.
73. Prat A, Pelletier D, Duquette P, Arnold DL, Antel JP. Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann Neurol 2000; 47(2):234-237.
74. Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Moller E et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A 1989; 86(18):7113-7117.
75. Weinshenker BG, Santrach P, Bissonet AS, McDonnell SK, Schaid D, Moore SB et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998; 51(3):742-747.
76. Hillert J, Gronning M, Nyland H, Link H, Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55(10):887-890.
77. Rovaris M, Bozzali M, Santuccio G, Iannucci G, Sormani MP, Colombo B et al. Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. J Neurol Neurosurg Psychiatry 2000; 69(6):723-727.
78. Lucchinetti C, Brack W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999; 122 (Pt 12):2279-2295.
79. Riise T, Gronning M, Klauber MR, Barrett-Connor E, Nyland H, Albrektsen G. Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway. Am J Epidemiol 1991; 133(9):932-939.
80. Eastman R, Sheridan J, Poskanzer DC. Multiple sclerosis clustering in a small Massachusetts community, with possible common exposure 23 years before onset. N Engl J Med 1973; 289(15):793-794.
81. Wikstrom J. Studies on the clustering of multiple sclerosis in Finland. Riv Patol Nerv Ment 1976; 97(4):199-204.
82. Hoffman RE, Zack MM, Davis LE, Burchfiel CM. Increased incidence and prevalence of multiple sclerosis in Los Alamos County, New Mexico. Neurology 1981; 31(11):1489-1492.
83. MacGregor HS. Multiple sclerosis clusters in Florida. J Epidemiol Community Health 1991; 45(1):88.
84. Hader WJ, Irvine DG, Schiefer HB. A cluster-focus of multiple sclerosis at Henribourg, Saskatchewan. Can J Neurol Sci 1990; 17(4):391-394.
85. Armon C, Daube JR, O'Brien PC, Kurland LT, Mulder DW. When is an apparent excess of neurologic cases epidemiologically significant? Neurology 1991; 41(11):1713-1718.
86. Riise T. Cluster studies in multiple sclerosis. Neurology 1997; 49(2 Suppl 2):S27-S32.
87. Granieri E, Casetta I, Tola MR, Govoni V, Paolino E, Malagu S et al. Multiple sclerosis: does epidemiology contribute to providing etiological clues? J Neurol Sci 1993; 115 Suppl:S16-S23.